{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:48:15Z","timestamp":1787327295629,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2020R1A5A2019413"],"award-info":[{"award-number":["2020R1A5A2019413"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S3302137"],"award-info":[{"award-number":["S3302137"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of therapeutic strategies to overcome resistance to anti-PD1 therapies in lung cancer remains a significant challenge. Based on our recent findings of SH003\u2019s immunomodulatory capabilities, this study investigates the combined effects of SH003 and docetaxel (DTX) as a potential second-line therapy in an anti-PD1-resistant lung cancer model. Our results demonstrate that SH003 and DTX effectively inhibit tumor growth by inducing apoptosis in an anti-PD1-resistant lung cancer LLC1 model, while enhancing the infiltration of cytotoxic CD8\n                    <jats:sup>\n                      <jats:bold>+<\/jats:bold>\n                    <\/jats:sup>\n                    T cells and NK cells into the tumor microenvironment (TME), thereby boosting anti-tumor immunity. SH003 also exhibited immunomodulatory effects in an immunosuppressed mouse model, further emphasizing its potential in enhancing immune responses. Notably, the combination treatment significantly inhibits tumor growth by targeting the EGFR\/JAK\/STAT3 signaling pathway, contributing to the reduction of PD-L1 expression associated with immune evasion. These findings elucidate the dual mechanism of action of the SH003-DTX combination in overcoming resistance through both direct anticancer effects and immune system modulation. Overall, these findings demonstrate that the SH003-DTX combination presents a promising approach for anti-PD1-refractory lung cancer patients, potentially offering new treatment possibilities where current options are limited.\n                  <\/jats:p>","DOI":"10.1007\/s00262-025-04064-6","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:29:34Z","timestamp":1746854974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The combination of SH003 and DTX induces cytotoxic cell infiltration in anti-PD1 resistant lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Yu-Jeong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-In","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Yong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Gyu","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"4064_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21811","author":"AMD Wolf","year":"2023","unstructured":"Wolf AMD, Oeffinger KC, Shih TY et al (2023) Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21811","journal-title":"CA Cancer J Clin"},{"key":"4064_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2022) Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:497\u2013530. https:\/\/doi.org\/10.6004\/jnccn.2022.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"4064_CR3","doi-asserted-by":"publisher","first-page":"6984948","DOI":"10.1155\/2018\/6984948","volume":"2018","author":"H Sui","year":"2018","unstructured":"Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, Yang J (2018) Anti-PD-1\/PD-L1 therapy for non-small-cell lung cancer: toward personalized medicine and combination strategies. J Immunol Res 2018:6984948. https:\/\/doi.org\/10.1155\/2018\/6984948","journal-title":"J Immunol Res"},{"key":"4064_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","volume":"19","author":"J Huynh","year":"2019","unstructured":"Huynh J, Chand A, Gough D, Ernst M (2019) Therapeutically exploiting STAT3 activity in cancer\u2014using tissue repair as a road map. Nat Rev Cancer 19:82\u201396. https:\/\/doi.org\/10.1038\/s41568-018-0090-8","journal-title":"Nat Rev Cancer"},{"key":"4064_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14566","volume":"9","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J (2023) Anti-PD-(L)1 therapy of non-small cell lung cancer\u2014a summary of clinical trials and current progresses. Heliyon 9:e14566. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14566","journal-title":"Heliyon"},{"key":"4064_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102303","volume":"66","author":"R Matsuzawa","year":"2023","unstructured":"Matsuzawa R, Morise M, Ito K et al (2023) Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine 66:102303. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102303","journal-title":"EClinicalMedicine"},{"key":"4064_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/492173","volume":"2014","author":"YK Choi","year":"2014","unstructured":"Choi YK, Cho SG, Woo SM, Yun YJ, Park S, Shin YC, Ko SG (2014) Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm 2014:492173. https:\/\/doi.org\/10.1155\/2014\/492173","journal-title":"Mediators Inflamm"},{"key":"4064_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41419-020-02924-w","volume":"11","author":"TW Kim","year":"2020","unstructured":"Kim TW, Cheon C, Ko SG (2020) SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells. Cell Death Dis 11:717. https:\/\/doi.org\/10.1038\/s41419-020-02924-w","journal-title":"Cell Death Dis"},{"key":"4064_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12906-016-1490-5","volume":"16","author":"YJ Choi","year":"2016","unstructured":"Choi YJ, Choi YK, Lee KM, Cho SG, Kang SY, Ko SG (2016) SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med 16:507. https:\/\/doi.org\/10.1186\/s12906-016-1490-5","journal-title":"BMC Complement Altern Med"},{"key":"4064_CR10","doi-asserted-by":"publisher","first-page":"3647900","DOI":"10.1155\/2022\/3647900","volume":"2022","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Lee K, Yoon JH et al (2022) SH003 and docetaxel show synergistic anticancer effects by inhibiting EGFR activation in triple-negative breast cancer. Biomed Res Int 2022:3647900. https:\/\/doi.org\/10.1155\/2022\/3647900","journal-title":"Biomed Res Int"},{"key":"4064_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168405","author":"MS Jeong","year":"2021","unstructured":"Jeong MS, Lee KW, Choi YJ et al (2021) Synergistic antitumor activity of SH003 and docetaxel via EGFR signaling inhibition in non-small cell lung cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22168405","journal-title":"Int J Mol Sci"},{"key":"4064_CR12","doi-asserted-by":"publisher","first-page":"4120334","DOI":"10.1155\/2021\/4120334","volume":"2021","author":"K Lee","year":"2021","unstructured":"Lee K, Ku JM, Choi YJ, Hwang HH, Jeong M, Kim YG, Kim MJ, Ko SG (2021) Herbal prescription SH003 alleviates docetaxel-induced neuropathic pain in C57BL\/6 mice. Evid Based Complement Alternat Med 2021:4120334. https:\/\/doi.org\/10.1155\/2021\/4120334","journal-title":"Evid Based Complement Alternat Med"},{"key":"4064_CR13","doi-asserted-by":"publisher","first-page":"114893","DOI":"10.1016\/j.jep.2021.114893","volume":"285","author":"NR Han","year":"2022","unstructured":"Han NR, Kim KC, Kim JS, Ko SG, Park HJ, Moon PD (2022) The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin. J Ethnopharmacol 285:114893. https:\/\/doi.org\/10.1016\/j.jep.2021.114893","journal-title":"J Ethnopharmacol"},{"key":"4064_CR14","doi-asserted-by":"publisher","first-page":"153473542412934","DOI":"10.1177\/15347354241293451","volume":"23","author":"C Cheon","year":"2024","unstructured":"Cheon C, Lee HW, Sym SJ, Ko SG (2024) Safety of the herbal medicine SH003 in patients with solid cancer: a multi-center, single-arm, open-label, dose-escalation phase I study. Integr Cancer Ther 23:15347354241293452. https:\/\/doi.org\/10.1177\/15347354241293451","journal-title":"Integr Cancer Ther"},{"key":"4064_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (2019) Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 39:147\u2013164. https:\/\/doi.org\/10.1200\/EDBK_240837","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4064_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ (2002) Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol 2:735\u2013747. https:\/\/doi.org\/10.1038\/nri911","journal-title":"Nat Rev Immunol"},{"key":"4064_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17:616\u2013623. https:\/\/doi.org\/10.1038\/cdd.2009.206","journal-title":"Cell Death Differ"},{"key":"4064_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001","journal-title":"Immunity"},{"key":"4064_CR19","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","volume":"184","author":"C Camisaschi","year":"2010","unstructured":"Camisaschi C, Casati C, Rini F et al (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184:6545\u20136551. https:\/\/doi.org\/10.4049\/jimmunol.0903879","journal-title":"J Immunol"},{"key":"4064_CR20","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR (2023) Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer 129:1212\u20131224. https:\/\/doi.org\/10.1038\/s41416-023-02361-4","journal-title":"Br J Cancer"},{"key":"4064_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","volume":"120","author":"NA Giraldo","year":"2019","unstructured":"Giraldo NA, Sanchez-Salas R, Peske JD et al (2019) The clinical role of the TME in solid cancer. Br J Cancer 120:45\u201353. https:\/\/doi.org\/10.1038\/s41416-018-0327-z","journal-title":"Br J Cancer"},{"key":"4064_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004433","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G (2021) Cytokines: from clinical significance to quantification. Adv Sci (Weinh) 8:e2004433. https:\/\/doi.org\/10.1002\/advs.202004433","journal-title":"Adv Sci (Weinh)"},{"key":"4064_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120:6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y","journal-title":"Br J Cancer"},{"key":"4064_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092178","author":"RM Morris","year":"2022","unstructured":"Morris RM, Mortimer TO, O\u2019Neill KL (2022) Cytokines: can cancer get the message? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14092178","journal-title":"Cancers (Basel)"},{"key":"4064_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao Q, Wang S, Chen X et al (2019) Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer 7:42. https:\/\/doi.org\/10.1186\/s40425-019-0511-6","journal-title":"J Immunother Cancer"},{"key":"4064_CR26","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B et al (2022) Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics 12:4965\u20134979. https:\/\/doi.org\/10.7150\/thno.73152","journal-title":"Theranostics"},{"key":"4064_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2174\/1386207322666190125150921","volume":"21","author":"CH Ru","year":"2018","unstructured":"Ru CH, Zhuang YB (2018) Efficacy and safety of addition of anti-PD1 to chemotherapy in treatment of non-small cell lung cancer. Comb Chem High Throughput Screen 21:711\u2013717. https:\/\/doi.org\/10.2174\/1386207322666190125150921","journal-title":"Comb Chem High Throughput Screen"},{"key":"4064_CR28","doi-asserted-by":"publisher","first-page":"1354794","DOI":"10.3389\/fphar.2024.1354794","volume":"15","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Wang J, Liang H, Guo W, Chu Y, Liu L, Kang W (2024) Prevention of cyclophosphamide-induced immune suppression by polysaccharides from Apocynum venetum flowers via enhancing immune response, reducing oxidative stress, and regulating gut microbiota in mice. Front Pharmacol 15:1354794. https:\/\/doi.org\/10.3389\/fphar.2024.1354794","journal-title":"Front Pharmacol"},{"key":"4064_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G et al (2017) Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90\u201395. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.034","journal-title":"Lung Cancer"},{"key":"4064_CR30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550\u20131558. https:\/\/doi.org\/10.1038\/s41591-018-0136-1","journal-title":"Nat Med"},{"key":"4064_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s44222-022-00016-2","volume":"1","author":"P Yousefpour","year":"2023","unstructured":"Yousefpour P, Ni K, Irvine DJ (2023) Targeted modulation of immune cells and tissues using engineered biomaterials. Nat Rev Bioeng 1:107\u2013124. https:\/\/doi.org\/10.1038\/s44222-022-00016-2","journal-title":"Nat Rev Bioeng"},{"key":"4064_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero I, Rouzaut A, Motz GT, Coukos G (2014) T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 4:522\u2013526. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0985","journal-title":"Cancer Discov"},{"key":"4064_CR33","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","volume":"75","author":"SF Ngiow","year":"2015","unstructured":"Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015) A threshold level of intratumor CD8+ T-cell PD1 Expression dictates therapeutic response to Anti-PD1. Cancer Res 75:3800\u20133811. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1082","journal-title":"Cancer Res"},{"key":"4064_CR34","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1158\/0008-5472.CAN-20-0471","volume":"80","author":"F Voli","year":"2020","unstructured":"Voli F, Valli E, Lerra L et al (2020) Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion. Cancer Res 80:4129\u20134144. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0471","journal-title":"Cancer Res"},{"key":"4064_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-023-02609-0","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu Q, Deng F et al (2023) HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res 42:38. https:\/\/doi.org\/10.1186\/s13046-023-02609-0","journal-title":"J Exp Clin Cancer Res"},{"key":"4064_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2022.06.001","volume":"26","author":"TW Kim","year":"2022","unstructured":"Kim TW, Kim Y, Keum H, Jung W, Kang M, Jon S (2022) Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Mol Ther Oncolytics 26:1\u201314. https:\/\/doi.org\/10.1016\/j.omto.2022.06.001","journal-title":"Mol Ther Oncolytics"},{"key":"4064_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12906-024-04347-y","volume":"24","author":"K Lee","year":"2024","unstructured":"Lee K, Choi YJ, Lim HI, Cho KJ, Kang N, Ko SG (2024) Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer. BMC Complement Med Ther 24:70. https:\/\/doi.org\/10.1186\/s12906-024-04347-y","journal-title":"BMC Complement Med Ther"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04064-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04064-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04064-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:01:38Z","timestamp":1749924098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04064-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04064-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"198"}}